JP2015513535A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015513535A5 JP2015513535A5 JP2014558090A JP2014558090A JP2015513535A5 JP 2015513535 A5 JP2015513535 A5 JP 2015513535A5 JP 2014558090 A JP2014558090 A JP 2014558090A JP 2014558090 A JP2014558090 A JP 2014558090A JP 2015513535 A5 JP2015513535 A5 JP 2015513535A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- phosphatidylserine
- use according
- receptor
- tim
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305193 | 2012-02-21 | ||
| EP12305193.0 | 2012-02-21 | ||
| EP12306281.2 | 2012-10-17 | ||
| EP12306281 | 2012-10-17 | ||
| PCT/EP2013/053391 WO2013124327A1 (en) | 2012-02-21 | 2013-02-20 | Tim receptors as virus entry cofactors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015513535A JP2015513535A (ja) | 2015-05-14 |
| JP2015513535A5 true JP2015513535A5 (enExample) | 2016-03-10 |
Family
ID=47739275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014558090A Pending JP2015513535A (ja) | 2012-02-21 | 2013-02-20 | ウイルス侵入補助因子としてのｔｉｍレセプター |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20160017035A1 (enExample) |
| EP (1) | EP2817327A1 (enExample) |
| JP (1) | JP2015513535A (enExample) |
| BR (1) | BR112014021068A8 (enExample) |
| IN (1) | IN2014DN07023A (enExample) |
| MX (1) | MX2014010016A (enExample) |
| WO (1) | WO2013124327A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014021065A8 (pt) | 2012-02-21 | 2018-04-24 | Centre Nat Rech Scient | receptores tam como cofatores de entrada do vírus |
| EP2931317A2 (en) * | 2012-12-13 | 2015-10-21 | Children's Medical Center Corporation | Compositions and methods for inhibiting viral entry |
| WO2015092035A1 (en) * | 2013-12-20 | 2015-06-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Cd300a receptors as virus entry cofactors |
| EP3206709A1 (en) * | 2014-10-15 | 2017-08-23 | Annexin Pharmaceuticals AB | Therapeutic composition comprising annexin v |
| CN113980089B (zh) * | 2014-12-05 | 2024-12-27 | 富士胶片株式会社 | 一种检测试样中的细胞外膜囊泡的方法和检测用试剂盒的用途 |
| KR102543118B1 (ko) | 2016-05-27 | 2023-06-14 | 아게누스 인코포레이티드 | 항-tim-3 항체 및 이의 사용 방법 |
| US20190248893A1 (en) | 2016-07-14 | 2019-08-15 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
| US20210024582A1 (en) * | 2018-03-29 | 2021-01-28 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Chimeric tim-3 fusion protein |
| US11197910B1 (en) * | 2020-08-19 | 2021-12-14 | Vitruviae LLC | Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases |
| CN119639892B (zh) * | 2024-11-13 | 2026-06-12 | 浙江大学 | 一种分子标志物tim1及其在卵巢透明细胞癌中的应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2135646A1 (en) | 1992-05-11 | 1993-11-25 | Kenneth G. Draper | Method and reagent for inhibiting viral replication |
| US6620805B1 (en) | 1996-03-14 | 2003-09-16 | Yale University | Delivery of nucleic acids by porphyrins |
| WO1997045442A1 (en) | 1996-05-24 | 1997-12-04 | Imperial College Of Science Technology And Medicine | Polycationic sterol derivatives as transfection agents |
| US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| US6001311A (en) | 1997-02-05 | 1999-12-14 | Protogene Laboratories, Inc. | Apparatus for diverse chemical synthesis using two-dimensional array |
| US20030229040A1 (en) | 1997-03-21 | 2003-12-11 | Georgetown University | Cationic liposomal delivery system and therapeutic use thereof |
| CA2289702C (en) | 1997-05-14 | 2008-02-19 | Inex Pharmaceuticals Corp. | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
| WO1999001579A1 (en) | 1997-07-01 | 1999-01-14 | Isis Pharmaceuticals, Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
| US20030073640A1 (en) | 1997-07-23 | 2003-04-17 | Ribozyme Pharmaceuticals, Inc. | Novel compositions for the delivery of negatively charged molecules |
| AU8525098A (en) | 1997-07-24 | 1999-02-16 | Inex Pharmaceuticals Corporation | Liposomal compositions for the delivery of nucleic acid catalysts |
| CA2326823A1 (en) | 1998-04-20 | 1999-10-28 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid molecules with novel chemical compositions capable of modulating gene expression |
| US7112337B2 (en) | 1999-04-23 | 2006-09-26 | Alza Corporation | Liposome composition for delivery of nucleic acid |
| US7098032B2 (en) | 2001-01-02 | 2006-08-29 | Mirus Bio Corporation | Compositions and methods for drug delivery using pH sensitive molecules |
| US20050037086A1 (en) | 1999-11-19 | 2005-02-17 | Zycos Inc., A Delaware Corporation | Continuous-flow method for preparing microparticles |
| JP2003535122A (ja) | 2000-06-02 | 2003-11-25 | ザイコス インク． | 生物活性物質のための送達システム |
| US7427394B2 (en) | 2000-10-10 | 2008-09-23 | Massachusetts Institute Of Technology | Biodegradable poly(β-amino esters) and uses thereof |
| HUP0303616A3 (en) | 2001-03-26 | 2006-07-28 | Alza Corp Mountain View | Liposome composition for improved intracellular delivery of a therapeutic agent |
| WO2002076427A2 (en) | 2001-03-26 | 2002-10-03 | Thomas Jefferson University | Ph sensitive liposomal drug delivery |
| US20030026831A1 (en) | 2001-04-20 | 2003-02-06 | Aparna Lakkaraju | Anionic liposomes for delivery of bioactive agents |
| JP2004535388A (ja) | 2001-04-30 | 2004-11-25 | ターゲティッド ジェネティクス コーポレイション | 脂質含有薬物送達複合体およびそれらの生成方法 |
| DE10127526A1 (de) | 2001-05-31 | 2002-12-12 | Novosom Ag | Verfahren zur Herstellung und Auflösung von Nano- und Mikrokapseln |
| US7101995B2 (en) | 2001-08-27 | 2006-09-05 | Mirus Bio Corporation | Compositions and processes using siRNA, amphipathic compounds and polycations |
| DE10152145A1 (de) | 2001-10-19 | 2003-05-22 | Novosom Ag | Stabilisierung von Liposomen und Emulsionen |
| JP2005527639A (ja) | 2001-11-02 | 2005-09-15 | インサート セラピューティクス インコーポレイテッド | Ｒｎａ干渉の治療的利用のための方法及び組成物 |
| WO2003057190A1 (en) | 2001-12-31 | 2003-07-17 | Elan Pharmaceuticals, Inc. | Efficient nucleic acid encapsulation into medium sized liposomes |
| WO2003066069A1 (en) | 2002-02-01 | 2003-08-14 | Intradigm Corporation | Polymers for delivering peptides and small molecules in vivo |
| US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
| CA2476769A1 (en) | 2002-02-22 | 2003-09-04 | Insert Therapeutics, Inc. | Carbohydrate-modified polymers, compositions and uses related thereto |
| US7037520B2 (en) | 2002-03-22 | 2006-05-02 | Baylor College Of Medicine | Reversible masking of liposomal complexes for targeted delivery |
| US20030198664A1 (en) | 2002-03-29 | 2003-10-23 | Sullivan Sean Michael | Lipid mediated screening of drug candidates for identification of active compounds |
| EP1507561B1 (en) | 2002-05-24 | 2009-07-15 | Mirus Bio Corporation | Compositions for delivering nucleic acids to cells |
| US7682626B2 (en) | 2003-02-07 | 2010-03-23 | Roche Madison Inc. | Polyvinylethers for delivery of polynucleotides to mammalian cells |
| WO2009001224A2 (en) | 2007-06-22 | 2008-12-31 | Eth Zurich | Antivirals |
| CA2703519C (en) | 2007-11-09 | 2017-04-18 | The Salk Institute For Biological Studies | Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors |
| WO2010043045A1 (en) | 2008-10-17 | 2010-04-22 | London Health Sciences Centre Research Inc. | Annexin and its use to treat inflammatory disorders |
| US9163087B2 (en) * | 2010-06-18 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions |
| BR112014021065A8 (pt) | 2012-02-21 | 2018-04-24 | Centre Nat Rech Scient | receptores tam como cofatores de entrada do vírus |
-
2013
- 2013-02-20 EP EP13704966.4A patent/EP2817327A1/en not_active Withdrawn
- 2013-02-20 IN IN7023DEN2014 patent/IN2014DN07023A/en unknown
- 2013-02-20 US US14/379,879 patent/US20160017035A1/en not_active Abandoned
- 2013-02-20 MX MX2014010016A patent/MX2014010016A/es unknown
- 2013-02-20 BR BR112014021068A patent/BR112014021068A8/pt not_active IP Right Cessation
- 2013-02-20 JP JP2014558090A patent/JP2015513535A/ja active Pending
- 2013-02-20 WO PCT/EP2013/053391 patent/WO2013124327A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2015042308A3 (en) | Rna-based hiv inhibitors | |
| Barcellini et al. | Rituximab therapy for autoimmune haematological diseases | |
| MX2019006411A (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos. | |
| JP2012126742A5 (enExample) | ||
| JP2013172734A5 (enExample) | ||
| JP2018530530A5 (enExample) | ||
| JP2014501492A5 (enExample) | ||
| EP4632075A3 (en) | Method for reducing immunogenicity of rna | |
| JP2017070307A5 (enExample) | ||
| JP2014513356A5 (enExample) | ||
| BRPI0813237B8 (pt) | composto, método para preparar o composto, medicamento, e, uso do composto | |
| JP2015521593A5 (enExample) | ||
| JP2013539454A5 (enExample) | ||
| MX357393B (es) | Formulaciones estabilizadas que contienen anticuerpos anti - ang2. | |
| BR112014019584A8 (pt) | Composto da fórmula (i), sua forma tautomérica, seu isômero, ou seu sal farmaceuticamente aceitável, composição farmacêutica, método de inibição da replicação de um vírus contendo rna, método de tratamento ou prevenção de infecção causada por um vírus contendo rna, e, método de tratamento de infecção por hepatite c | |
| JP2011136997A5 (enExample) | ||
| FI3581650T3 (fi) | IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi | |
| WO2013006795A3 (en) | Antiviral compositions and methods of their use | |
| JP2018510132A5 (enExample) | ||
| JP2015518494A5 (enExample) | ||
| JP2013503110A5 (enExample) | ||
| JP2014503593A5 (enExample) | ||
| MX2010002018A (es) | Peptido de cdh3 y agente medicinal que comprende al mismo. | |
| CL2011001977A1 (es) | Compuestos derivados de triazolopiridina, inhibidores de proteinas cinasas activadas por mitogeno p38; composicion farmaceutica; y su uso para el tratamiento de neumonia eosinofilica cronica, asma, enfermedad pulmonar obstructiva cronica y sindrome de angustia respiratoria en adultos, entre otras enfermedades. | |
| WO2013036622A3 (en) | Antiviral peptides effective against hepatitis c virus |